|
Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 12, Num. 2, 1995, pp. 78-79
|
Revista Biotecnologia Aplicada 12(2): 78-79
(1995)
REPORTE CORTO/SHORT REPORT
Presented in the Congress Biotecnologia Habana 94. La Habana,
Cuba, Nov. 28 - Dec. 3, 1994
THREE-STEP IMMUNOSCINTIGRAPHY WITH THE AVIDIN-BIOTIN SYSTEM:
STATE OF THE ART AND FUTURE PROSPECTIVES
G. Paganelli^1, C. Songini^2, P. Magnani^2, A. Samuel^2, F.
Sudati^2, L. Lopalco^2, A. Sidoli^2, A. G. Siccardi^2 and F.
Fazio^2.
^2INB-CNR, University of Milan, Scientific Institute H.S.
Raffaele. ^1Istituto Europeo di Oncologia, Milano, Italy.
Code Number: BA95019
File Sizes:
Text: 7K
No associated graphics
INTRODUCTION
Specific targeting of radioactive agents to tumor cells has been
a major goal of the in vivo use of monoclonal antibodies
(Mab) for diagnostic and therapeutic purposes. However, only a
relatively small amount of the injected dose of Mabs is bound by
the tumor, while Mab conjugated to radioisotope keep circulating
in the blood stream and in normal tissue. Also circulating Mabs,
especially when bound to a beta emiting isotope, are obviously
undesirable and should be limited in order to protect normal
tissue such as bone marrow.
Antibody fragments, such as F(ab')[2] or Fab have a faster blood
clearance than whole antibodies, to the exent of allowing the use
of short-lived radionuclides such as ^99mTc with good diagnostic
sensitivity. This improvement, however, does not yield tumor to
background rations high enough to allow low-risk therapeutical
applications.
Strategies of tumor pre-targeting, where Mab and radiolabel are
administered separately have been proposed to reduce the
background noise due to circulating antibodies (1-4). A 3-step
immunoscintigraphy (3-S-ISG) using the avidin-biotin system has
been used in cancer patients (5).
MATERIALS AND METHODS
Injection of biotinylated Mab (first step) is followed by avidin
(second step) in order to precipitate circulating biotinylated
Mab and at the same time to target the tumor cells allowing
adequate homing in of the subsequently administered labelled
biotin (third step). From early 1990 to Novembrer 1993 we have
studied and followed up 127 patients according with the protocol
described above using different Mabs specific for different
tumors including colon and lung cancer, gliomas, melanomas and
apudomas.
RESULTS
The method has shown to be safe, reliable and of clinical utility
since an overall sensitivity of 88% with 94% specifity and 84%
accurancy was demonstrated. Moreover, 38 unknow lesions in 25
patients were localized and 21 were confirmed in their follow-up.
Of these patients, 16 had not evidence of disease at the time of
3-S ISG but only increased tumor markers. The immunoresponse
against biotinylated mouse IgG (HAMA) and avidin (HAAR) was
evaluated in 73 patients. None developed HAMA after the injection
of 1-2 mg of whole biotinylated IgG and 8/73 patients developed
a weak HAAR response. However, radioactivity delivered per gram
of tumor was in the range of 0.01-0.001% i.d., still below the
optimal dose for radioimmunotherapy. This was probably due to the
fact that avidin blood clearance is very fast with a T1/12 of 82
minutes. Thus, we are now developing a recombinant avidin
molecule in order to reduce the immunogenicity and improve it
pharmacokinetic in view of a therapeutical application of this
approach to cancer treatment.
DISCUSSION
Tumor pretargeting methods with the 3-step approach have been
shown to offer several advantages over the administration of
directly labelled Mabs. In particular since the label is a small
molecule, with a fast blood clearance background radioactivity
levels are drastically reduced and imaging can be performed
shortly after injection of the radiolabel. The 3-step protocol
is designed to remove the excess circulating biotinylated
antibodies as cold complexes and this is obtained prior to label
injection.
The use of unlabelled, unfragment antibodies also avoids their
damage by autoradiolysis and by enzyme treatments. Given that
more than one molecule of avidin can bind to a single
polybiotinylated Mab molecule localized on the tumor, and that
up to three radioactive biotin molecules can bind to an avidin
molecule this approach is also designed to provide an
amplification of the signal from the tumor.
Moreover, one can use any Mab from a panel, or Mab mixtures: the
second and third steps of the three-step protocol would be common
to all studies and the use of a cocktail would enhance the
possibilities of targeting more tumor cells by using different
tumor antigens as target. For successful diagnosis as well as
therapy the tumor must be covered as much as possible in
avidin.
These protocols have now been optimized and can potentially be
applied widely in the majority of solid tumors including breast,
lung, colon, ovary and others malignacies.
Techniques employed in genetic engineering will be able to
provide chimeric proteins made up of antibody fragments and
recombinant avidin in order to obtain an antibody molecule
conjugated with a modified avidin tetramer of low
immunogenicity.
REFERENCES
1. HNATOWICH, D. J. et al. (1987). Investigations of
avidin and biotin for imaging applications. Journal Nuclear
Medicine 28:1294
2. LE DOUSSAL, J. M. et al. (1989). in vitro and
in vivo targeting of radiolabeled monovalent and divalent
haptenss with dual specificity monoclonal antibody conjugates:
enchanced divalent hapten affinity for cell-bound antibody
conjugated. Journal Nuclear Medicine 30:1358.
3. LESLIE, A. et al. (1993). Improved Immunotargeting
of Tumors with Biotinylated Monoclonal Antibody.
Immunoconjugates, and Radiopharmaceuticals 6 (1):
13-27.
4. PAGANELI, G. et al. (1992). Two-step tumour
targetting in ovarian cancer patients using biotinylated
monoclonal antibodies and radioactive streptavidin. European
Journal of Nuclear Medicine 19:322.
5. PAGANELLI, G. et al. (1991). Three-step monoclonal
antibody tumor targeting in carcinoembryonic antigen-positive
patients. Cancer Research 51:5960
Copyright 1995 Sociedad Iberolatinoamericana de Biotecnologia
Aplicada a la Salud
|